Class-Action Securities Suits On The Rise Against Life-Science Firms, Especially Smaller Ones
Executive Summary
A recent report from law firm Dechert LLP shows that the number of class-action cases brought against life-sciences companies has spiked in recent years, up from 27 in 2012 to 88 in 2017. The trend is most pronounced against smaller-cap companies, an attorney behind the report explains.